Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Unicycive Therapeutics Inc (UNCY)

Unicycive Therapeutics Inc (UNCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 132,814
  • Shares Outstanding, K 21,491
  • Annual Sales, $ 0 K
  • Annual Income, $ -36,730 K
  • EBIT $ -32 M
  • EBITDA $ -31 M
  • 60-Month Beta 1.85
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.91

Options Overview Details

View History
  • Implied Volatility 294.73% (-38.60%)
  • Historical Volatility 63.34%
  • IV Percentile 16%
  • IV Rank 20.01%
  • IV High 714.84% on 11/12/25
  • IV Low 189.63% on 11/11/25
  • Expected Move (DTE 4) 1.36 (22.90%)
  • Put/Call Vol Ratio 0.20
  • Today's Volume 12
  • Volume Avg (30-Day) 151
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 2,149
  • Open Int (30-Day) 1,178
  • Expected Range 4.58 to 7.30

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.56
  • Number of Estimates 4
  • High Estimate -0.35
  • Low Estimate -0.80
  • Prior Year -2.60
  • Growth Rate Est. (year over year) +78.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.35 +10.37%
on 12/18/25
6.35 -7.01%
on 01/09/26
-0.32 (-5.22%)
since 12/12/25
3-Month
4.28 +37.97%
on 11/07/25
6.95 -14.97%
on 12/09/25
+1.47 (+33.00%)
since 10/10/25
52-Week
3.71 +59.16%
on 09/25/25
11.00 -46.32%
on 06/09/25
-0.74 (-11.12%)
since 01/10/25

Most Recent Stories

More News
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)

LOS ALTOS, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for...

UNCY : 5.80 (-6.15%)
Unicycive Therapeutics to Participate in Upcoming Investor Events in December

LOS ALTOS, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company”...

UNCY : 5.80 (-6.15%)
Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

-   Remain on track to resubmit the New Drug Application (NDA) for oxylanthanum carbonate (OLC) by year end -   Presented new analysis of OLC data at American Society of Nephrology (ASN) which...

UNCY : 5.80 (-6.15%)
Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

LOS ALTOS, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company”...

UNCY : 5.80 (-6.15%)
Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference

LOS ALTOS, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company”...

UNCY : 5.80 (-6.15%)
Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End

LOS ALTOS, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the Company...

UNCY : 5.80 (-6.15%)
UNCY Deadline Today: Rosen Law Firm Urges Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between March 29,...

UNCY : 5.80 (-6.15%)
Did You Lose Money on Unicycive Therapeutics, Inc. (UNCY)? Levi & Korsinsky Urges Investors to Act Before October 14, 2025

New York, New York--(Newsfile Corp. - October 14, 2025) - If you suffered a loss on your Unicycive Therapeutics, Inc. (NASDAQ: UNCY) investment and want to learn about a potential recovery under the federal...

UNCY : 5.80 (-6.15%)
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit

NEW YORK , Oct. 14, 2025 /PRNewswire/ --

UNCY : 5.80 (-6.15%)
Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - UNCY

LOS ANGELES , Oct. 13, 2025 /PRNewswire/ --  The DJS Law Group  reminds investors of a class action lawsuit against Unicycive Therapeutics, Inc. ("Unicycive" or "the Company") (NASDAQ: UNCY...

UNCY : 5.80 (-6.15%)

Business Summary

Unicycive Therapeutics Inc. is a clinical stage biotechnology company. It involved in developing therapies for patients with kidney disease. The company's lead drug consist Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. Unicycive Therapeutics Inc....

See More

Key Turning Points

3rd Resistance Point 6.70
2nd Resistance Point 6.53
1st Resistance Point 6.35
Last Price 5.80
1st Support Level 6.00
2nd Support Level 5.83
3rd Support Level 5.65

See More

52-Week High 11.00
Fibonacci 61.8% 8.22
Fibonacci 50% 7.36
Fibonacci 38.2% 6.49
Last Price 5.80
52-Week Low 3.71

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar